t-Butyl-β-D-xylopyranosid | 6758-44-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: t-Butyl-β-D-xylopyranosid
• 英文别名: tert-butyl-β-D-xylopyranoside；tert-Butyl-β-D-xylopyranosid；(2S,3R,4S,5R)-2-[(2-methylpropan-2-yl)oxy]oxane-3,4,5-triol
• CAS: 6758-44-7
• 化学式: C₉H₁₈O₅
• 分子量: 206.239
• InChiKey: FLHUMSLBAXHIOK-CWKFCGSDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  79.2
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2,3,4-三-O-乙酰基-α-D-木吡喃糖苷溴 在 silver carbonate 、 苯 作用下， 生成 t-Butyl-β-D-xylopyranosid
  参考文献：
  名称：

  Janson; Lindberg, Acta Chemica Scandinavica (1947), 1959, vol. 13, p. 138,142

  摘要：

  DOI：

文献信息

• SIRTUIN MODULATING COMPOUNDS
  申请人：Nunes Joseph J.

  公开号：US20120197013A1

  公开（公告）日：2012-08-02

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了一种新颖的调节沉默信息调节因子（sirtuin）的化合物及其使用方法。这些调节sirtuin的化合物可用于延长细胞寿命，并用于治疗和/或预防多种疾病和障碍，包括与衰老或应激有关的疾病或障碍、糖尿病、肥胖症、神经退行性疾病、心血管疾病、血液凝结障碍、炎症、癌症和/或潮红，以及需要增加线粒体活性的疾病或障碍。还提供了包含sirtuin调节化合物与另一种治疗药物组合的组合物。
• Stereoselective protecting-group-free synthesis of alkyl glycosides using dibenzyloxy triazine type glycosyl donors
  作者：Gefei Li、Masato Noguchi、Masaki Ishihara、Yuka Takagi、Marina Nagaki、Sachie Saito、Masashi Saito、Xin-shan Ye、Shin-ichiro Shoda

  DOI：10.1016/j.carres.2023.108940

  日期：2023.12

  key step for the synthesis of sugar-containing molecules such as glycolipids. However, traditional carbohydrate chemistry is characterized by extensive use of protective groups, resulting in laborious manipulations and poor atom economy. Here, we present a protecting-group-free glycosylation strategy employing dibenzyloxy-1,3,5-triazin-2-yl glycosides (DBT-glycosides) as glycosyl donors. The DBT-glycosyl

  化学O-糖基化是合成糖脂等含糖分子的关键步骤。然而，传统的碳水化合物化学的特点是广泛使用保护基团，导致操作繁琐且原子经济性差。在这里，我们提出了一种使用二苄氧基-1,3,5-三嗪-2-基糖苷（DBT-糖苷）作为糖基供体的无保护基糖基化策略。 DBT-糖基供体可以通过水介质中未受保护的糖的碱性亲核取代直接制备。在温和的氢解条件下，使用 DBT-糖基供体对醇进行O-糖基化，以良好的产率立体选择性地提供相应的烷基糖苷。
• COMPOSITIONS AND METHODS RELATED TO SIRT1 FUNCTION
  申请人：Sassone-Corsi Paolo

  公开号：US20110269817A1

  公开（公告）日：2011-11-03

  The invention relates to modulation of circadian rhythm and underlying biological processes.
• METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES
  申请人：Roth Mark B.

  公开号：US20120135091A1

  公开（公告）日：2012-05-31

  The present invention concerns the use of active compounds, including chalcogenides and sirtuin-modulating compounds, either alone or in combination for increasing or enhancing survivability and/or longevity in biological matter. In general aspects, the chalcogenides and other active compounds may modulate one or more sirtuin proteins. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described.
• US8163908B2
  申请人：——

  公开号：US8163908B2

  公开（公告）日：2012-04-24